Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration

Jiaojiao He, Ke Wang, Ningning Zheng, Yunping Qiu, Guoxiang Xie, Mingming Su, Wei Jia, Houkai Li

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Metformin is a widely used anti-diabetic drug with potential anti-tumor activity. However, little is known about its global metabolic and transcriptional impacts on tumor cells. In current study, we performed a metabolic profiling on human-derived colon cancer LoVo cells treated by 10 mM metformin for 8, 24 and 48 h. An obvious time-dependent metabolic alteration was observed from 8 to 48 h, prior to the reduction of cell viability. A total of 47, 45 and 66 differential metabolites were identified between control and metformin-treated cells at three time points. Most of the metabolites were up-regulated at 8 h, but down-regulated at 24 and 48 h by metformin. These metabolites were mainly involved in carbohydrates, lipids, amino acids, vitamins and nucleotides metabolism pathways. Meanwhile, the transcirptomic profile revealed 134 and 3061 differentially expressed genes at 8 and 24 h by metformin. In addition to the cancer signaling pathways, expression of genes involved in cell energy metabolism pathways was significantly altered, which were further validated with genes in glucose metabolism pathway. Altogether, our current data indicate that metformin suppressed the proliferation of LoVo cells, which may be due to the modulation on cell energy metabolism at both metabolic and transcriptional levels in a time-dependent way.

Original languageEnglish (US)
Article number17423
JournalScientific Reports
Volume5
DOIs
StatePublished - Nov 30 2015

Fingerprint

Metformin
Cell Proliferation
Energy Metabolism
Neoplasms
Vitamins
Colonic Neoplasms
Genes
Cell Survival
Nucleotides
Carbohydrates
Lipids
Gene Expression
Amino Acids
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration. / He, Jiaojiao; Wang, Ke; Zheng, Ningning; Qiu, Yunping; Xie, Guoxiang; Su, Mingming; Jia, Wei; Li, Houkai.

In: Scientific Reports, Vol. 5, 17423, 30.11.2015.

Research output: Contribution to journalArticle

He, Jiaojiao ; Wang, Ke ; Zheng, Ningning ; Qiu, Yunping ; Xie, Guoxiang ; Su, Mingming ; Jia, Wei ; Li, Houkai. / Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration. In: Scientific Reports. 2015 ; Vol. 5.
@article{0f02d5f7d3c14bef912d5672db1c0b71,
title = "Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration",
abstract = "Metformin is a widely used anti-diabetic drug with potential anti-tumor activity. However, little is known about its global metabolic and transcriptional impacts on tumor cells. In current study, we performed a metabolic profiling on human-derived colon cancer LoVo cells treated by 10 mM metformin for 8, 24 and 48 h. An obvious time-dependent metabolic alteration was observed from 8 to 48 h, prior to the reduction of cell viability. A total of 47, 45 and 66 differential metabolites were identified between control and metformin-treated cells at three time points. Most of the metabolites were up-regulated at 8 h, but down-regulated at 24 and 48 h by metformin. These metabolites were mainly involved in carbohydrates, lipids, amino acids, vitamins and nucleotides metabolism pathways. Meanwhile, the transcirptomic profile revealed 134 and 3061 differentially expressed genes at 8 and 24 h by metformin. In addition to the cancer signaling pathways, expression of genes involved in cell energy metabolism pathways was significantly altered, which were further validated with genes in glucose metabolism pathway. Altogether, our current data indicate that metformin suppressed the proliferation of LoVo cells, which may be due to the modulation on cell energy metabolism at both metabolic and transcriptional levels in a time-dependent way.",
author = "Jiaojiao He and Ke Wang and Ningning Zheng and Yunping Qiu and Guoxiang Xie and Mingming Su and Wei Jia and Houkai Li",
year = "2015",
month = "11",
day = "30",
doi = "10.1038/srep17423",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration

AU - He, Jiaojiao

AU - Wang, Ke

AU - Zheng, Ningning

AU - Qiu, Yunping

AU - Xie, Guoxiang

AU - Su, Mingming

AU - Jia, Wei

AU - Li, Houkai

PY - 2015/11/30

Y1 - 2015/11/30

N2 - Metformin is a widely used anti-diabetic drug with potential anti-tumor activity. However, little is known about its global metabolic and transcriptional impacts on tumor cells. In current study, we performed a metabolic profiling on human-derived colon cancer LoVo cells treated by 10 mM metformin for 8, 24 and 48 h. An obvious time-dependent metabolic alteration was observed from 8 to 48 h, prior to the reduction of cell viability. A total of 47, 45 and 66 differential metabolites were identified between control and metformin-treated cells at three time points. Most of the metabolites were up-regulated at 8 h, but down-regulated at 24 and 48 h by metformin. These metabolites were mainly involved in carbohydrates, lipids, amino acids, vitamins and nucleotides metabolism pathways. Meanwhile, the transcirptomic profile revealed 134 and 3061 differentially expressed genes at 8 and 24 h by metformin. In addition to the cancer signaling pathways, expression of genes involved in cell energy metabolism pathways was significantly altered, which were further validated with genes in glucose metabolism pathway. Altogether, our current data indicate that metformin suppressed the proliferation of LoVo cells, which may be due to the modulation on cell energy metabolism at both metabolic and transcriptional levels in a time-dependent way.

AB - Metformin is a widely used anti-diabetic drug with potential anti-tumor activity. However, little is known about its global metabolic and transcriptional impacts on tumor cells. In current study, we performed a metabolic profiling on human-derived colon cancer LoVo cells treated by 10 mM metformin for 8, 24 and 48 h. An obvious time-dependent metabolic alteration was observed from 8 to 48 h, prior to the reduction of cell viability. A total of 47, 45 and 66 differential metabolites were identified between control and metformin-treated cells at three time points. Most of the metabolites were up-regulated at 8 h, but down-regulated at 24 and 48 h by metformin. These metabolites were mainly involved in carbohydrates, lipids, amino acids, vitamins and nucleotides metabolism pathways. Meanwhile, the transcirptomic profile revealed 134 and 3061 differentially expressed genes at 8 and 24 h by metformin. In addition to the cancer signaling pathways, expression of genes involved in cell energy metabolism pathways was significantly altered, which were further validated with genes in glucose metabolism pathway. Altogether, our current data indicate that metformin suppressed the proliferation of LoVo cells, which may be due to the modulation on cell energy metabolism at both metabolic and transcriptional levels in a time-dependent way.

UR - http://www.scopus.com/inward/record.url?scp=84948799023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948799023&partnerID=8YFLogxK

U2 - 10.1038/srep17423

DO - 10.1038/srep17423

M3 - Article

C2 - 26616174

AN - SCOPUS:84948799023

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 17423

ER -